lunes, 18 de abril de 2016

Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy. - PubMed - NCBI

Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy. - PubMed - NCBI



 2016 Apr 8. [Epub ahead of print]

Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.

Abstract

Practice guidelines incorporate genomic tumor profiling, using results such as the Oncotype DX Recurrence Score (RS), to refine recurrence risk estimates for the large proportion of breast cancer patients with early-stage, estrogen receptor-positive disease. We sought to understand the impact of receiving genomic recurrence risk estimates on breast cancer patients' well-being and the impact of these patient-reported outcomes on receipt of adjuvant chemotherapy. Participants were 193 women (mean age 57) newly diagnosed with early-stage breast cancer. Women were interviewed before and 2-3 weeks after receiving the RS result between 2011 and 2015. We assessed subsequent receipt of chemotherapy from chart review. After receiving their RS, perceived pros (t = 4.27, P < .001) and cons (t = 8.54, P < .001) of chemotherapy increased from pre-test to post-test, while perceived risk of breast cancer recurrence decreased (t = 2.90, P = .004). Women with high RS tumors were more likely to receive chemotherapy than women with low RS tumors (88 vs. 5 %, OR 0.01, 0.00-0.02, P < .001). Higher distress (OR 2.19, 95 % CI 1.05-4.57, P < .05) and lower perceived cons of chemotherapy (OR 0.50, 95 % CI 0.26-0.97, P < .05) also predicted receipt of chemotherapy. Distressed patients who saw few downsides of chemotherapy received this treatment. Clinicians should consider these factors when discussing chemotherapy with breast cancer patients.

KEYWORDS:

21-Gene; Breast cancer; Chemotherapy; Treatment decisions

PMID:
 
27059031
 
[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario